While severe throbbing head pain is the most recognized feature of a migraine, the associated sensory and gastrointestinal symptoms often cause equal impairment. Nausea, vomiting, photophobia (sensitivity to light), and phonophobia (sensitivity to sound) can turn a routine headache into a disabling episode requiring complete rest in a dark, quiet room.
When evaluating modern acute migraine treatments, regulatory agencies like the FDA require evidence of efficacy across co-primary endpoints. A successful acute treatment must demonstrate superiority over placebo not only in pain freedom at two hours, but also in eliminating the patient's "most bothersome" associated symptom.
The clinical trials investigating oral CGRP antagonists evaluated this multi-symptom relief directly. In randomized, double-blind trials, active doses of telcagepant (150 mg and 300 mg) achieved statistically significant superiority over placebo across all five co-primary endpoints at two hours post-dose: pain freedom, pain relief, absence of photophobia, absence of phonophobia, and absence of nausea. Furthermore, efficacy was sustained over a 24-hour window, reducing the likelihood of headache recurrence.
This comprehensive symptom relief highlights the biological role of CGRP. CGRP receptors are widely distributed throughout the trigeminovascular system, central nervous system, and gastrointestinal tract. Blocking CGRP signaling dampens both central pain processing and peripheral neurogenic inflammation. By addressing the full spectrum of migraine pathology rather than simply constricting blood vessels, CGRP-targeted therapies offer patients holistic relief from both pain and its accompanying sensory disturbances.